BioSpectrum Asia’s cover story in its December edition reflects on the advancement and changes that have shaped the industry in 2023. Cartherics’ COO, Dr Ian Nisbet contributed to the article, commenting on the challenges for life sciences companies in the region, particularly smaller and private companies, to raise new capital. He also discussed the impact of the current funding environment on publicly listed companies.

The article discusses:

• AI in drug discovery
• China’s role as a biopharma innovator – becoming a sought-after destination for ground-breaking therapies, attracting major deals with prominent global pharmaceutical and biotech firms
• Mental health and ageing
• Singapore’s emergence as a hotbed for biopharma manufacturing
• Genomic testing and precision medicines
• New diagnostic tech
• The funding drought
• APAC being the favoured destination for clinical trials
• Innovations in CAR-T cell therapies

Read the complete article here: https://www.biospectrumasia.com/analysis/25/23386/buoyant-life-sciences-sector-emerges-stronger.html